Chinese facility changes hands from GSK to Fosun Pharmaceutical


The deal has been reported to be worth US$36 million

A manufacturing facility in Suzhou, China has been purchased by Fosun Pharmaceuticals from GSK. The deal has been reported to be worth US$36 million, according to a company state.

The new owners of the facility west of Shanghai said that the plant produced a revenue of $94.4m in 2018.

The deal will also allow YaoPharma, Fosun's Chongqing unit, to acquire all production facilities and authorisations for the GSK plant's chronic hepatitis B drug lamivudine.

Sign up for your free email newsletter

The news of this sale comes as GSK announced the opening of its new API continuous manufacturing facility in Singapore. This will be a big shift in manufacturing focus in the Asian region for the pharma giant.